Occurrence of Jaundice Following Simultaneous Ursodeoxycholic Acid Cessation and Obeticholic Acid Initiation
Sign Up to like & getrecommendations! Published in 2017 at "Digestive Diseases and Sciences"
DOI: 10.1007/s10620-017-4900-8
Abstract: Primary biliary cholangitis (PBC) is a chronic autoimmune cholestatic disease for which ursodeoxycholic acid (UDCA) has been the mainstay of treatment. Obeticholic acid (OCA) emerged in 2016 as a second agent for PBC treatment. It… read more here.
Keywords: initiation; ursodeoxycholic acid; jaundice; obeticholic acid ... See more keywords
FDA rejects NASH drug
Sign Up to like & getrecommendations! Published in 2020 at "Nature Reviews Drug Discovery"
DOI: 10.1038/d41573-020-00126-9
Abstract: cholic acid for fibrosis due to nonalcoholic steatohepatitis (NASH), another setback for an indication beset with failures. NASH is a form of liver disease that is marked by excessive fat accumulation, inflammation and cellular damage… read more here.
Keywords: nash drug; liver; drug; obeticholic acid ... See more keywords
The FXR Agonist, Obeticholic Acid, Suppresses HCC Proliferation & Metastasis: Role of IL-6/STAT3 Signalling Pathway
Sign Up to like & getrecommendations! Published in 2017 at "Scientific Reports"
DOI: 10.1038/s41598-017-12629-4
Abstract: The nuclear receptor, farnesoid X receptor (FXR), has been recently considered as a tumor suppressor in HCC. IL-6/Janus kinase 2 (Jak-2)/signal transducer and activator of transcription 3 (STAT3) pathway has been implicated as a key… read more here.
Keywords: fxr agonist; stat3; obeticholic acid; agonist obeticholic ... See more keywords
Combined obeticholic acid and elafibranor treatment promotes additive liver histological improvements in a diet-induced ob/ob mouse model of biopsy-confirmed NASH
Sign Up to like & getrecommendations! Published in 2019 at "Scientific Reports"
DOI: 10.1038/s41598-019-45178-z
Abstract: Obeticholic acid (OCA) and elafibranor (ELA) are selective and potent agonists for the farnesoid X receptor (FXR) and dual peroxisome proliferator-activated receptor α/δ (PPAR-α/δ), respectively. Both agents have demonstrated clinical efficacy in nonalcoholic steatohepatitis (NASH).… read more here.
Keywords: biopsy confirmed; confirmed nash; diet induced; obeticholic acid ... See more keywords
FXR-Dependent Modulation of the Human Small Intestinal Microbiome by the Bile Acid Derivative Obeticholic Acid.
Sign Up to like & getrecommendations! Published in 2018 at "Gastroenterology"
DOI: 10.1053/j.gastro.2018.08.022
Abstract: BACKGROUND & AIMS Intestinal bacteria can modify the composition of bile acids and bile acids, which are regulated by the farnesoid X receptor, affect the survival and growth of gut bacteria. We studied the effects… read more here.
Keywords: bile acids; small intestinal; microbiome; obeticholic acid ... See more keywords
Greater Transplant-free Survival in Patients Receiving Obeticholic Acid for Primary Biliary Cholangitis in a Clinical Trial Setting Compared to Real-World External Controls.
Sign Up to like & getrecommendations! Published in 2022 at "Gastroenterology"
DOI: 10.1053/j.gastro.2022.08.054
Abstract: BACKGROUND AND AIMS The POISE randomized double-blind placebo-controlled trial demonstrated that obeticholic acid (OCA) reduced biomarkers associated with adverse clinical outcomes (ALP, bilirubin, AST, ALT) in patients with primary biliary cholangitis (PBC). The objective of… read more here.
Keywords: primary biliary; trial; biliary cholangitis; obeticholic acid ... See more keywords
Reduction and stabilization of bilirubin with obeticholic acid treatment in patients with primary biliary cholangitis
Sign Up to like & getrecommendations! Published in 2020 at "Liver International"
DOI: 10.1111/liv.14429
Abstract: Total bilirubin is a predictor of survival in primary biliary cholangitis, with the main elevated component being direct bilirubin. The purpose of this post hoc analysis was to assess the efficacy and safety of obeticholic… read more here.
Keywords: primary biliary; reduction stabilization; stabilization bilirubin; obeticholic acid ... See more keywords
Predictors of serious adverse events and non‐response in cirrhotic patients with primary biliary cholangitis treated with obeticholic acid
Sign Up to like & getrecommendations! Published in 2022 at "Liver International"
DOI: 10.1111/liv.15386
Abstract: Obeticholic acid (OCA) has recently been restricted in patients with primary biliary cholangitis (PBC) with “advanced cirrhosis” because of its narrow therapeutic index. We aimed to better define the predicting factors of hepatic serious adverse… read more here.
Keywords: primary biliary; biliary cholangitis; serious adverse; obeticholic acid ... See more keywords
Obeticholic Acid Derivative, T-2054 Suppresses Osteoarthritis via Inhibiting NF-κB-Signaling Pathway
Sign Up to like & getrecommendations! Published in 2021 at "International Journal of Molecular Sciences"
DOI: 10.3390/ijms22083807
Abstract: Osteoarthritis (OA), a degenerative joint disorder, has been reported as the most common cause of disability worldwide. The production of inflammatory cytokines is the main factor in OA. Previous studies have been reported that obeticholic… read more here.
Keywords: raw 264; acid derivative; obeticholic acid; signaling pathway ... See more keywords
Obeticholic Acid: A New Era in the Treatment of Nonalcoholic Fatty Liver Disease
Sign Up to like & getrecommendations! Published in 2018 at "Pharmaceuticals"
DOI: 10.3390/ph11040104
Abstract: The main treatments for patients with nonalcoholic fatty liver disease (NAFLD) are currently based on lifestyle changes, including ponderal decrease and dietary management. However, a subgroup of patients with nonalcoholic steatohepatitis (NASH), who are unable… read more here.
Keywords: fatty liver; treatment; obeticholic acid; nonalcoholic fatty ... See more keywords
Obeticholic Acid Reduces Kidney Matrix Metalloproteinase Activation Following Partial Hepatic Ischemia/Reperfusion Injury in Rats
Sign Up to like & getrecommendations! Published in 2022 at "Pharmaceuticals"
DOI: 10.3390/ph15050524
Abstract: We have previously demonstrated that the farnesoid X receptor (FXR) agonist obeticholic acid (OCA) protects the liver via downregulation of hepatic matrix metalloproteinases (MMPs) after ischemia/reperfusion (I/R), which can lead to multiorgan dysfunction. The present… read more here.
Keywords: partial hepatic; reperfusion; obeticholic acid; hepatic ischemia ... See more keywords